Alkeon Capital Management
LKFT

Alkeon Capital Management’s Lakefront Biotherapeutics American Depositary Shares LKFT Stock Holding History

Alkeon Capital Management’s Portfolio LKFT Stock Details LKFT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-175,000
Closed -$20.6M – 148
2019
Q1 		$20.6M Buy
+175,000
New +$17.6M 0.1% 103

Other funds holding LKFT

Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Bessemer Group
Bessemer Group Woodbridge, New Jersey $63.6B AUM 28.76% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Alkeon Capital Management's LKFT Position: Q2 2019 in Review

Alkeon Capital Management sold out of Lakefront Biotherapeutics American Depositary Shares (LKFT) in Q2 2019, closing a stake of 175,000 shares — an estimated $20.6M sold.

Alkeon Capital Management first reported a position in LKFT in Q1 2019 and held it in 1 quarter. The position peaked at $20.6M in Q1 2019. 102 funds tracked by Wall St. Rank hold LKFT as of Q2 2019.

  • Alkeon Capital Management reported no remaining Lakefront Biotherapeutics American Depositary Shares position as of Q2 2019 after selling out during the quarter.
  • Alkeon Capital Management sold 175,000 Lakefront Biotherapeutics American Depositary Shares shares in Q2 2019, an estimated $20.6M.
  • Alkeon Capital Management first reported a position in Lakefront Biotherapeutics American Depositary Shares in Q1 2019 and held it in 1 quarter.
  • Alkeon Capital Management's Lakefront Biotherapeutics American Depositary Shares position peaked at $20.6M in Q1 2019.
  • 102 funds tracked by Wall St. Rank held Lakefront Biotherapeutics American Depositary Shares as of Q2 2019.

Based on Alkeon Capital Management's 13F filing for Q2 2019, filed 14 Aug 2019.